TIMP-2 gene therapy

Drug Profile

TIMP-2 gene therapy

Latest Information Update: 29 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Coronary artery restenosis

Most Recent Events

  • 29 Apr 2002 No development reported - Preclinical for Coronary artery restenosis in USA (IV)
  • 02 Mar 1999 An animal study has been added to the pharmacodynamic section of Cancer chemotherapy
  • 02 Mar 1999 Preclinical development for Cancer in Italy (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top